ArticleJCO precision oncology2020
Emergence of Concurrent Multiple
Article in JCO precision oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Clinical Significance of Extrachromosomal DNA inJCO precision oncology · 2025Article
- A Case of Advanced Biliary Tract Cancer With EGFR Amplification That Responded to Necitumumab.Cancer reports (Hoboken, N.J.) · 2024Article
- New therapeutic target molecules for gastric and gastroesophageal junction cancer.International journal of clinical oncology · 2024Review
- EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.International journal of molecular sciences · 2024Article
- Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer.Frontiers in oncology · 2024Review
- Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond.Cancers · 2022Review
- Opportunities and challenges of targeting c-Met in the treatment of digestive tumors.Frontiers in oncology · 2022Review
- EGFR Amplification in Metastatic Colorectal Cancer.Journal of the National Cancer Institute · 2021Article
- Circulating Tumor DNA Analysis DetectsClinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.Nature reviews. Clinical oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.